{"originalText": "，2016-4月间断便血1月。外院肠镜见距肛门10CM。病理为高级别下皮内瘤变,部分可见黏膜内癌，完善分期检查，CT3N2B，外科建议术前放化疗，2016-5-12至2016-6-3完成GTV 51GY CTV 40.8GY/34F BID D1-D5/W。2016-8-11行LAR手术，，术后病理：直肠中分化腺癌，部分伴细胞外黏液，，肿瘤消退分级：轻度反应，未见脉管癌栓及神经侵犯；肠周淋巴结7/9，另见多个癌结节（>10）,病理分期YPT3N2B,CM0。术后辅以化疗8周期（XELOX*5，卡培他滨单药*3），末次化疗时间2017-1；治疗结束后定期复查，CT未见明显异常；2017-7-11至2017-10-13期间多次复查CEA由7.32升至22.69；CA125由15.10升至55.38；CA199由57.10升至152.70；CA74-2由37.75升至23.55；，2017-9-18：外院，PET-CT：直肠术后，右侧肠壁增厚伴代谢活性稍高，上腹部沿大网膜及肠系膜走形多发结节影伴代谢活性轻度增高，考虑转移可能性大，腹膜后淋巴结显示，不伴代谢升高，骶前软组织密度影伴环形代谢活性增强，考虑包裹性积液；2017-10月 我院行XELOX+安维汀治疗2周期。", "entities": [{"label_type": "解剖部位", "overlap": 0, "start_pos": 21, "end_pos": 27}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 31, "end_pos": 39}, {"end_pos": 144, "label_type": "手术", "overlap": 0, "start_pos": 139}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 151, "end_pos": 158}, {"end_pos": 198, "label_type": "解剖部位", "overlap": 0, "start_pos": 193}, {"end_pos": 253, "label_type": "药物", "overlap": 0, "start_pos": 249}, {"label_type": "影像检查", "overlap": 0, "start_pos": 282, "end_pos": 284}, {"label_type": "实验室检验", "overlap": 0, "start_pos": 317, "end_pos": 320}, {"label_type": "实验室检验", "overlap": 0, "start_pos": 333, "end_pos": 338}, {"label_type": "实验室检验", "overlap": 0, "start_pos": 352, "end_pos": 357}, {"label_type": "实验室检验", "overlap": 0, "start_pos": 372, "end_pos": 378}, {"label_type": "影像检查", "overlap": 0, "start_pos": 406, "end_pos": 412}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 413, "end_pos": 417}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 420, "end_pos": 421}, {"end_pos": 435, "label_type": "解剖部位", "overlap": 0, "start_pos": 432}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 440, "end_pos": 441}, {"end_pos": 475, "label_type": "解剖部位", "overlap": 0, "start_pos": 469}, {"end_pos": 487, "label_type": "解剖部位", "overlap": 0, "start_pos": 485}, {"end_pos": 532, "label_type": "药物", "overlap": 0, "start_pos": 529}]}
